Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Common Equity (2016 - 2025)

Historic Common Equity for Rhythm Pharmaceuticals (RYTM) over the last 10 years, with Q3 2025 value amounting to $148.8 million.

  • Rhythm Pharmaceuticals' Common Equity rose 122694.61% to $148.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $148.8 million, marking a year-over-year increase of 122694.61%. This contributed to the annual value of $21.7 million for FY2024, which is 8720.01% down from last year.
  • Rhythm Pharmaceuticals' Common Equity amounted to $148.8 million in Q3 2025, which was up 122694.61% from -$11.9 million recorded in Q2 2025.
  • Rhythm Pharmaceuticals' Common Equity's 5-year high stood at $380.9 million during Q1 2021, with a 5-year trough of -$11.9 million in Q2 2025.
  • In the last 5 years, Rhythm Pharmaceuticals' Common Equity had a median value of $195.6 million in 2022 and averaged $177.6 million.
  • Over the last 5 years, Rhythm Pharmaceuticals' Common Equity had its largest YoY gain of 122694.61% in 2025, and its largest YoY loss of 13026.71% in 2025.
  • Quarter analysis of 5 years shows Rhythm Pharmaceuticals' Common Equity stood at $284.2 million in 2021, then dropped by 7.0% to $264.3 million in 2022, then tumbled by 35.76% to $169.8 million in 2023, then plummeted by 87.2% to $21.7 million in 2024, then soared by 584.88% to $148.8 million in 2025.
  • Its last three reported values are $148.8 million in Q3 2025, -$11.9 million for Q2 2025, and $18.9 million during Q1 2025.